peptides for healing

the healing-peptide shelf is built on rodent data. zero compounds in this category have a phase-3 tendon or wound-repair indication.

as of may 2026 no peptide marketed for tendon, ligament, or soft-tissue healing has an fda-approved repair indication. bpc-157 has 200+ rodent papers from the sikiric zagreb lab and zero phase-3 rcts. tb-500 was isolated by goldstein in 1981 and banned by USEF in 2014. ghk-cu has the best cosmetic record in the category but the connective-tissue case is mostly extrapolation. kpv is a three-residue alpha-msh fragment with promising colitis biology in mice.

blend rows grade their named components, not a fixed product. gut-barrier, tissue-protection, immune, bone-fracture, and patient-neurology evidence does not establish generic tendon, ligament, or wound repair.

the repair cluster.

compounds most often discussed in tendon, ligament, wound, and soft-tissue contexts. evidence is strongest mechanistically and in rodent models, thinner in controlled human trials.

ghk-cu (tier S) · copper-binding tripeptide isolated from human plasma by Pickart in 1973. modulates 4,192 genes in fibroblast genomics (Pickart, BioMed Res Int 2010).
bpc-157 (tier A) · 15-amino-acid gastric pentadecapeptide. 200+ rodent papers from the Sikiric lab in Zagreb. zero phase-3 rcts as of may 2026.
tb-500 (tier A) · thymosin beta-4 fragment. parent peptide isolated by Goldstein in 1981 from thymus tissue. banned by USEF in 2014 as a horse-doping agent.
bpc-157 + tb-500 blend (tier A) · two repair-pathway peptides paired for local signaling plus cell-migration biology.

adjacent biology, thinner outcomes.

these compounds appear in healing searches, but the evidence points to inflammation, mitochondrial disease, or bone-fracture outcomes rather than direct tendon, ligament, or wound repair.

klow (tier A) · kpv, bpc-157, ghk-cu, and tb-500 in one compounded blend.
ss-31 (tier A) · elamipretide, mitochondria-targeted tetrapeptide. FDA accelerated approval september 2025 (Forzinity) for Barth syndrome, a rare cardiolipin disorder.
kpv (tier B) · lysine-proline-valine. c-terminal tripeptide of alpha-msh. picomolar nf-kb inhibition in dss-colitis mouse models (Kannengiesser et al, IBD 2008).
tb-500 fragment (tier C) · short actin-binding fragment of thymosin beta-4. typically the LKKTETQ heptapeptide.
Abaloparatide (tier S) · Abaloparatide is an FDA-approved subcutaneous bone-anabolic peptide for high-risk osteoporosis. It reduced vertebral fractures in studied postmenopausal women; it is not an adult-height intervention.
larazotide (tier D) · larazotide acetate (AT-1001) is an eight-amino-acid oral tight-junction regulator. a celiac phase 2b found a symptom benefit at 0.5 mg three times daily, but the pivotal phase 3 was terminated after an interim sample-size review and posted no results.
ghk-cu + bpc blend (tier A) · the surface-and-structure repair pairing. ghk-cu rebuilds skin and collagen, bpc-157 works on connective tissue and gut. component evidence first, fixed-blend trial evidence absent.
bpc-157 + kpv blend (tier A) · gut and systemic anti-inflammatory repair. bpc-157 carries the blend, kpv adds the NF-kB anti-inflammatory leg. strong mechanism, thinner human proof on the second component.
cibinetide (tier D) · eleven amino acids copied from erythropoietin, the hormone that tells the body to make more red blood cells. the copy keeps the half of that hormone which protects injured tissue and leaves the red cells alone. vendors label it ARA-290. six published human trials, five of them randomised, and two primary endpoints that separated.
vip (tier D) · a chemical the body makes in its own gut, lungs and nerves to widen blood vessels and relax the muscle in the walls of airways and gut. drug companies made a synthetic copy of it and took it into trials for damaged lungs. four randomized trials in COVID-19 respiratory failure, a 665-patient meta-analysis, and a plasma half-time of about one minute. the biggest trial was stopped for futility. the one trial that clearly beat placebo is for erectile dysfunction, an indication nobody researches it for.
Cartalax (tier C) · an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.

specific-question reference.

which peptides have the strongest tissue-repair evidence?

bpc-157 and tb-500 dominate the preclinical repair literature. bpc-157 carries 200+ rodent papers from the sikiric lab in zagreb. tb-500 has the goldstein 1981 thymus-isolation lineage and decades of actin-dynamics work. controlled human outcome data for both: zero phase-3 rcts as of may 2026. ghk-cu has a stronger cosmetic and wound-remodeling record than most compounds in the category.

is any peptide fda-approved for tendon or ligament healing?

no. zero peptides in this category have an fda-approved tendon or ligament repair indication. ss-31 (elamipretide / forzinity) is approved for barth syndrome, not soft-tissue repair. fda-approved status in another context does not transfer to orthopedic injury.

what does the literature say about bpc-157 plus tb-500?

the combination is mechanistically coherent. bpc-157 maps to local signaling, nitric-oxide release, and angiogenesis. tb-500 maps to actin dynamics and cell migration. controlled human trial of the combination: none on pubmed as of may 2026.

do healing peptides replace rehab or imaging?

no. published peptide research does not substitute for diagnosis, imaging, surgical evaluation, or progressive loading. the serious literature on tendon and ligament recovery still routes through mechanical rehabilitation and clinician oversight.

what the safety literature reports.

what safety gap matters most in healing peptides?

long-term human safety characterization. BPC-157 and TB-500 have heavy community use and preclinical research. neither has the formal chronic-use human safety package expected of approved drugs. on april 22, 2026 the FDA removed both molecules from category 2 of the section 503A bulk-substances list, scheduling a PCAC review on july 23, 2026 specifically because that human-safety data does not exist.

why does regulatory status matter here?

because repair claims become treatment claims fast. once a compound is framed as healing an injury, the standard shifts from supplement to drug. that is the gap between rodent data and fda label.

what is the cleanest way to read this category?

as a mechanism map. bpc-157, tb-500, ghk-cu, and kpv point at different repair and inflammatory pathways. the map is not a protocol.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.